A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer

The basis of drug treatment for advanced-stage ovarian cancer in the first-line setting is
platinum (cisplatin or carboplatin) plus taxane (paclitaxel or docetaxel), with or without
bevacizumab. First line treatment regimens often result in high response rates, but most
tumors will recur within 2 years and patients die within 3 to 4 years of diagnosis. If a
patient progresses after 2 consecutive regimens without a response (refractory) or has
recurrent ovarian cancer within 6 months from their last platinum-based regimen
(platinum-resistant), prognosis is poor. The absence of an approved treatment or standard of
care in the recurrent setting represents an unmet need.

Early NCI studies in the 1970s and 1980s support VAL-083 activity in ovarian cancer. Interest
in this agent for ovarian cancer has recently re-emerged. The unique functional groups and
cytotoxic mechanisms are hoped to provide a viable novel treatment option in patients with
recurrent ovarian cancer that was resistant to platinum chemotherapies.

This is an open label, multi-center, Phase 1/2 clinical trial in subjects with recurrent
adenocarcinoma of the ovary who have been previously treated with a minimum of two courses of
platinum-based chemotherapy, and up to two additional cytotoxic regimens that may also have
included platinum (no more than four total lines of prior therapy), with or without
bevacizumab, whose cancer has recurred within six months of the most recent platinum-based
chemotherapy.

Study subjects will initially receive VAL-083 60 mg/m2 i.v. once weekly. If this regimen is
well tolerated for at least three sequential weekly treatments, the patient's dose may be
escalated to 67 mg/m2 i.v. If the 67 mg/m2 dose is well tolerated for at least three
sequential weekly treatments, the patient's dose may be escalated to 75 mg/m2 i.v. once
weekly for the remainder of the study. Dosing will continue once weekly for 16 weeks or until
disease progression, development of other unacceptable toxicity, death, withdrawal of
consent, loss to follow-up, or Sponsor ending the study, whichever occurs first. The
treatment plan is to enroll a minimum number of 20 subjects in Phase 1, followed by expansion
of enrollment in Phase 2 using the optimal dosing regimen determined in Phase 1.

Hematological safety assessments will be conducted at Screening and weekly before each
treatment. Clinical evaluations for physical examination, vital signs, disease symptoms,
quality of life measures (FOSI and opioid pain medication use), adverse events and
concomitant medications will be completed while the subject remains on study treatment.
Radiographic assessments (computed tomography [CT] or magnetic resonance imaging [MRI]) to
obtain tumor measurements and CA-125 concentration will be conducted at Screening and every 8
weeks while on study treatment, independent of dose delays and/or dose interruptions, until
progression of disease is suspected.

Pharmacokinetics will be evaluated in each of the first 10 subjects who have plasma samples
drawn on Day 1 of study treatment: pre-dose, then 15 ± 5 min, 30 ± 5 min, 60 ± 10 min, 120 ±
10 min, 240 ± 15 min, and 360 ± 15 min after the end of i.v. infusion with VAL-083.

A post-treatment safety assessment is to be scheduled 28 ±7 days after the last dose of study
treatment.

Follow-up for subjects terminating from study for any reason other than withdrawal of consent
will be done to allow an exploratory assessment of survival. All anti-tumor treatments
received after discontinuing treatment with VAL-083 will be collected, if available, and
survival status will also be reported to the Sponsor, on a monthly basis, when survival data
are available. In addition to survival, this assessment includes outcomes for subsequent
anticancer therapies including any new malignancy information. Date and cause of death will
be recorded.

The primary reason for study completion and discontinuation from monthly follow-up will be
captured for each study subject.

Inclusion Criteria:

1. Patient must willingly provide written consent after being informed of the procedure
to be followed, the experimental nature of the therapy, alternatives, potential
benefits, side effects, risks, and discomforts. (Human protection committee approval
of this protocol and consent form is required).

2. Must be ≥18 years old.

3. Histologically-confirmed initial diagnosis of adenocarcinoma of the ovary (AO),
excluding clear cell, low grade serous, mucinous adenocarcinoma or carcinosarcoma.

4. Subjects must have completed and failed a minimum of 2 previous lines of
platinum-containing therapy (e.g., carboplatin, oxaliplatin, or cisplatin).

5. Subjects may have failed up to 2 additional cytotoxic regimens that may have included
platinum.

6. Subjects must have had no more than 4 lines of prior drug therapy.

7. If treated with bevazicumab, subjects should have completed and failed treatment.

8. Subjects with BRCA mutation (positive) should have completed and failed treatment with
a PARP inhibitor, or have been ineligible for treatment with a PARP inhibitor.

9. Patient must have had documented best response, disease recurrence, and date of
progression based on RECIST v1.1 or CGIG criteria within 6 months from the start of
last prior platinum-based therapy.

10. Formalin fixed, paraffin-embedded archival tumor available from the primary or
recurrent cancer required.

11. Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of
≤ 2 and have been stable during wash-out period from prior therapy.

12. Adequate recovery from all recent surgery is required; at least 1 week must have
elapsed from the time of a minor surgery; at least 21 days must have elapsed from the
time of a major surgery. Must have recovered from all surgery-related toxicities to
Grade 1 or less.

13. A minimum of 28 days between termination of the investigational drug and
administration of VAL 083.

14. Must have recovered from all prior treatment-related toxicities to Grade 1 or less.

15. Laboratory values as follows at screening and within 3 days of planned first dose of
therapy:

1. Absolute neutrophil count (ANC) ≥ 1500/μL

2. Hemoglobin (HgB) ≥ 9 g/dL

3. Platelets ≥ 100,000/μL ( > 150,000/μL if prior nitrosureas)

4. Serum creatinine ≤ 1.5 × upper limit of normal (ULN) or creatinine clearance > 60
mL/min (measured or calculated by the Cockcroft-Gault formula) (Cockcroft &
Gault, 1976)

5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be < 2 ×
ULN unless liver metastases are present, in which case they must be ≤ 5 × ULN.

6. Total bilirubin < 1.5 × the institutional ULN, unless the patient has documented
conjugated bilirubin disorder such as Gilbert's syndrome. Subjects with known
Gilbert's disease who have serum bilirubin ≤ 3 × ULN (NCI CTCAE v4.03 Grade 2)
may be enrolled.

7. International normalized ratio (INR) ≤ 1.5 and activated partial thromboplastin
time (aPTT) ≤ 1.5 × ULN

16. Heart-rate corrected QT interval (QTc) < 450 msec on screening EKG.

17. No clinically significant cardiac conduction disorder on screening.

18. Subjects must be willing and able to comply with scheduled visits, treatment plan, and
laboratory tests and be accessible for follow-up.

Exclusion Criteria:

1. Subjects with clear cell, low grade serous or mucinous adenocarcinoma, or
carcinosarcoma.

2. Current history of neoplasm other than the entry diagnosis. Subjects with previous
cancers treated and cured with local therapy alone may be considered with approval of
the Medical Monitor.

3. Persistent Grade ≥2 toxicity from prior cancer therapy.

4. Subjects with declining ECOG performance status, defined by 1 point over a 28-day
period, will be excluded.

5. Concurrent severe, intercurrent illness including, but not limited to unstable
systemic disease, including ongoing or active infection, uncontrolled hypertension,
serious cardiac arrhythmia requiring medication, or psychiatric illness/social
situations that would limit compliance with study requirements.

6. Any of the following cardiac conditions:

1. History of myocardial infarction, acute coronary syndromes (including unstable
angina), coronary angioplasty, and/or stenting up to 12 weeks before initiation
of treatment with VAL-083

2. Class III or IV heart failure as defined by the New York Heart Association
functional classification system up to 6 months before initiation of treatment
with VAL-083

7. Subjects with known active hepatic disease (i.e., hepatitis B or C).

8. Subjects known to be HIV positive and not on stable medication or have an AIDS-related
illness.

9. Subjects with a known sensitivity to any of the products to be administered during
treatment and assessments.